Literature DB >> 10201672

The pharmacokinetics of milrinone in pediatric patients after cardiac surgery.

J M Bailey1, B E Miller, W Lu, S R Tosone, K R Kanter, V K Tam.   

Abstract

BACKGROUND: Milrinone has been shown to increase cardiac output in children after cardiac surgery, but pharmacokinetic analysis has not been used to identify effective dose regimens. The purpose of this study was to characterize the pharmacokinetics of milrinone in infants and children and to apply the results to the issue of dosing.
METHODS: Twenty children were studied after they underwent repair of congenital cardiac defects. Control hemodynamic measurement was made after the children were separated from cardiopulmonary bypass, and each patient was given a loading dose of 50 microg/kg progressively in 5 min. Hemodynamic measurements were recorded again at the end of the loading dose and when a blood sample was taken to determine milrinone plasma concentrations. Further blood samples were taken during the next 16 h for milrinone plasma concentration analysis. The pharmacokinetics of milrinone were analyzed using the population pharmacokinetic program NONMEM.
RESULTS: The loading dose of milrinone resulted in a mean decrease in mean blood pressure of 12% and a mean increase in cardiac index of 18% at a mean peak plasma concentration of 235 ng/ml. The pharmacokinetics of milrinone were best described by a three-compartment model. In the optimal model, all volumes and distribution clearances were proportional to weight, and weight-normalized elimination clearance was proportional to age; ie., Cl1 = 2.5 x weight x (1 + 0.058 x age) where Cl1 is expressed as ml/min, and the units of weight and age are kg and months, respectively.
CONCLUSIONS: A loading dose of 50 microg/kg effectively increases cardiac index in children after cardiac surgery. Simulations indicate that the peak plasma concentration can be maintained by following the loading dose of 50 microg/kg with an infusion of approximately 3 microg x kg(-1) x min(-1) for 30 min and then a maintenance infusion, which may require adjustment for age.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201672     DOI: 10.1097/00000542-199904000-00014

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  18 in total

Review 1.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

2.  Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease.

Authors:  Gonzalo Garcia Guerra; Ari R Joffe; Ambikaipakan Senthilselvan; Demetrios J Kutsogiannis; Christopher S Parshuram
Journal:  Intensive Care Med       Date:  2013-02-22       Impact factor: 17.440

3.  Use of milrinone in critically ill children.

Authors:  Teresa Bishara; Winnie T W Seto; Angela Trope; Christopher S Parshuram
Journal:  Can J Hosp Pharm       Date:  2010-11

4.  Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.

Authors:  Winnie Vogt
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

5.  Population pharmacokinetics and dosing regimen design of milrinone in preterm infants.

Authors:  Mary Paradisis; Xuemin Jiang; Andrew J McLachlan; Nick Evans; Martin Kluckow; David Osborn
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-05-11       Impact factor: 5.747

6.  Use of milrinone in the management of haemodynamic instability following duct ligation.

Authors:  Arvind Sehgal; Johny V Francis; Anthony I Lewis
Journal:  Eur J Pediatr       Date:  2010-09-17       Impact factor: 3.183

7.  Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery.

Authors:  Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

8.  A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery.

Authors:  James M Bailey; Timothy M Hoffman; David L Wessel; David P Nelson; Andrew M Atz; Anthony C Chang; Thomas J Kulik; Thomas L Spray; Akbar Akbary; Richard P Miller; Gil Wernovsky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

Review 9.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

Review 10.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.